이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Acrux 대차 대조표 상태

재무 상태 기준 확인 6/6

Acrux 의 총 주주 지분은 A$5.6M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$12.0M 및 A$6.4M 입니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	n/a
현금	AU$4.57m
주식	AU$5.64m
총 부채	AU$6.38m
총 자산	AU$12.02m

최근 재무 상태 업데이트

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14

재무 상태 분석

단기부채: ACR 의 단기 자산 ( A$9.2M )이 단기 부채( A$4.4M ).

장기 부채: ACR 의 단기 자산( A$9.2M )이 장기 부채( A$2.0M ).

부채 대 자본 내역 및 분석

부채 수준: ACR 부채가 없습니다.

부채 감소: ACR 지난 5년간 부채가 없습니다.

부채 범위: ACR 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: ACR 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Acrux 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Recent updates

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기